10-Q: RAPT Therapeutics Q3 2025: Ozureprubart Advances, Funds Raised

RAPT Therapeutics reported Q3 2025 results, highlighting positive Phase 2 data for ozureprubart in CSU and a successful $234.4 million public offering to fund ongoing clinical development.

Summary

• RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on inflammatory, immunological diseases, and oncology.
• The lead drug candidate, ozureprubart (formerly RPT904), is a half-life extended monoclonal antibody for allergic diseases, with a Phase 2b clinical trial initiated in food allergy in October 2025.
• Positive topline data from Jeyou's Phase 2 trial of ozureprubart in Chronic Spontaneous Urticaria (CSU) were announced in October 2025, showing comparable efficacy and safety to omalizumab at longer dosing intervals (Q8W/Q12W vs. Q4W).
• The oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist, for which the company is seeking a partner for further development outside the Hanmi Territory.
• Development of zelnecirnon, a small molecule CCR4 antagonist for inflammatory disease, was ceased in November 2024 following a serious adverse event (liver failure) in a Phase 2 trial and FDA feedback.
• Net loss for the nine months ended September 30, 2025, was $52.4 million, a decrease from $76.6 million for the same period in 2024.
• As of September 30, 2025, cash and cash equivalents and marketable securities totaled $157.3 million.
• In October 2025, the company completed an underwritten public offering of 8,333,334 shares of common stock at $30.00 per share, generating approximately $234.4 million in net proceeds.
• A 1-for-8 reverse stock split was effected on June 16, 2025.
• A workforce reduction impacting approximately 40% (47 people) of headcount was approved in July 2024 to conserve cash resources.

Sentiment

Score: 7

Explanation: The company reported a reduced net loss and positive Phase 2 clinical data for its lead candidate, ozureprubart, which is a significant step forward. The successful $234.4 million public offering substantially improves its liquidity and cash runway. However, the company continues to incur significant losses, has an accumulated deficit, and previously ceased development of another drug candidate due to safety concerns, indicating inherent risks in drug development.

Positives

• Positive topline data from Jeyou's Phase 2 trial of ozureprubart in Chronic Spontaneous Urticaria (CSU) demonstrated comparable efficacy and safety to omalizumab at longer dosing intervals (Q8W/Q12W vs. Q4W).
• Initiated a Phase 2b clinical trial of ozureprubart in food allergy in October 2025, expanding the clinical pipeline.
• Net loss significantly decreased to $52.4 million for the nine months ended September 30, 2025, from $76.6 million in the prior year, indicating improved financial performance.
• Research and development expenses decreased by 40% for the nine months ended September 30, 2025, primarily due to the strategic cessation of the zelnecirnon program.
• Successfully completed an underwritten public offering in October 2025, raising approximately $234.4 million in net proceeds, substantially strengthening the cash position and extending the cash runway.
• Other income, net, increased by 32% for the three months and 15% for the nine months ended September 30, 2025, driven by higher invested cash balances.

Negatives

• Continued to incur significant net losses, with $17.6 million for the three months and $52.4 million for the nine months ended September 30, 2025.
• Accumulated deficit reached $666.9 million as of September 30, 2025, reflecting a history of substantial losses since inception.
• Ceased development of zelnecirnon in November 2024 due to a serious adverse event (liver failure) in a Phase 2 trial and subsequent FDA feedback, representing a program failure.
• Implemented a workforce reduction of approximately 40% (47 people) in July 2024 to conserve cash, which may carry operational and reputational risks.
• Cash and cash equivalents decreased from $169.7 million at December 31, 2024, to $37.9 million at September 30, 2025, prior to the October 2025 public offering.
• Net cash used in operating activities was $76.1 million for the nine months ended September 30, 2025.
• No product revenue has been generated since inception, and profitability is not expected in the foreseeable future.

Risks

• Current or future product candidates may fail or suffer delays in clinical development, materially and adversely affecting their commercial viability.
• The company has a history of losses and expects to continue incurring significant losses for the foreseeable future, potentially never achieving or maintaining profitability.
• There is no guarantee of success in building a pipeline of drug candidates, and the organization has no history of successfully developing drugs to commercialization.
• The market may not be receptive to current or potential future drug candidates, potentially preventing revenue generation from sales or licensing.
• Undesirable side effects caused by current or potential future drug candidates could compromise the ability to market and derive revenue, as seen with zelnecirnon.
• Substantial additional funds are needed to discover and advance drug candidates, and there is no guarantee of sufficient future funding on acceptable terms.
• Reliance on third parties for preclinical studies and clinical trials introduces risks of non-performance, failure to satisfy regulatory requirements, or missed deadlines.
• Reliance on third-party, potentially sole-source, vendors for manufacturing and supply of drug candidates poses risks of limited or interrupted supply or unsatisfactory quality.
• The company faces intense competition from larger, better-funded entities with significant clinical experience.
• Inability to develop internal sales, marketing, and distribution capabilities or secure favorable third-party agreements could hinder commercialization.
• International operations expose the company to business, political, operational, and financial risks, including those related to partners in China and Korea.
• Business operations could be materially and adversely affected by disease outbreaks, epidemics, and pandemics.
• Inability to obtain, maintain, enforce, or defend intellectual property rights could impair competitive effectiveness.
• Stringent and evolving U.S. and foreign data privacy and security laws, regulations, and contractual obligations pose risks of investigations, litigation, fines, and reputational harm.
• The company's stock price may be volatile, leading to substantial losses for purchasers of common stock.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies or drug candidates.
• Principal stockholders own a significant percentage of stock, enabling them to exert significant control over matters subject to stockholder approval.
• Delays or difficulties may arise in transitioning responsibilities following the July 2024 workforce reduction.
• Inability to conduct or contract for animal testing in the future could harm research and development activities.
• Manufacturing processes are subject to FDA and other regulatory authority review, with risks of non-compliance with cGMP.
• Market opportunities for current and potential future drug candidates may be smaller than anticipated.
• Inability to attract and retain qualified key management, technical personnel, and employees could impair business plan implementation.
• Difficulties in managing growth and expanding operations could arise.
• Expenditure of limited resources on a particular drug candidate may lead to failure to capitalize on more profitable opportunities.
• Inability to enter into collaborations or strategic transactions on acceptable terms could adversely affect development and commercialization.
• Clinical development is a lengthy, expensive process with an uncertain outcome, and earlier results may not be predictive of future trial results.
• Inability to obtain U.S. or foreign regulatory approval could prevent commercialization.
• Even if approved, drug candidates will be subject to ongoing regulatory obligations and review, potentially incurring significant additional expense.
• Unfavorable pricing regulations or third-party coverage and reimbursement policies could harm the business.
• Non-compliance with U.S. and foreign anti-corruption and anti-money laundering laws can subject the company to criminal or civil liability.
• Significant product liability risk exists, and insufficient insurance coverage could have a material adverse effect.
• Employees, principal investigators, consultants, and commercial partners may engage in misconduct or improper activities.
• Compromise of information technology systems or data could lead to adverse consequences, including regulatory actions and litigation.
• Non-compliance with laws regulating environmental protection and health and human safety could adversely affect the business.
• Environmental, social, and governance (ESG) matters and related reporting obligations may impact the business.
• Quarterly operating results may fluctuate significantly or fall below expectations, causing stock price volatility.
• If securities or industry analysts do not publish research or issue adverse opinions, stock price and trading volume could decline.
• Ability to use net operating loss carryforwards (NOLs) and certain other tax attributes may be subject to limitations.
• Changes in tax laws or regulations could adversely affect the business.
• No anticipated cash dividends; capital appreciation will be the sole source of gain for the foreseeable future.
• Risk of significant costs from class action litigation due to stock volatility.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Exclusive forum provisions in the certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company expects to incur substantial expenditures in the foreseeable future as it expands its pipeline and advances drug candidates through clinical development, regulatory approval, and potential commercialization. Current cash and marketable securities, including proceeds from the October 2025 public offering, are believed to be sufficient to fund operations for at least 12 months from the filing date. Additional capital will be needed to support continuing operations and development strategy, which the company intends to raise through equity, debt, or strategic alliances. Plans include discussing advancement of ozureprubart to Phase 3 clinical development for CSU with regulatory authorities and seeking a partner for tivumecirnon development outside the Hanmi Territory. Research and development expenditures are expected to increase compared to 2024 (excluding the ozureprubart upfront license fee), and general and administrative expenses are also anticipated to rise as a public company, particularly if it is no longer classified as a smaller reporting company.

Management Comments

• "We and Jeyou believe these results warrant advancing ozureprubart to phase 3 development, and we plan to discuss our next steps regarding development for CSU with the FDA and other regulatory authorities."
• "We believe that our current cash and cash equivalents and marketable securities will provide sufficient funds to enable us to meet its obligations for at least 12 months from the filing date of this Quarterly Report on Form 10-Q."

Industry Context

The company operates in the highly competitive biopharmaceutical industry, focusing on immunology, inflammatory diseases, and oncology. Its lead candidate, ozureprubart, aims to compete with established anti-IgE antibodies like omalizumab (Xolair), seeking to offer improved therapeutic options. The oncology candidate, tivumecirnon, is being developed in a competitive landscape for non-small cell lung cancer, potentially in combination with checkpoint inhibitors like pembrolizumab. The industry is subject to increasing scrutiny regarding ESG practices, evolving data privacy regulations, and significant healthcare legislative reforms (e.g., ACA, IRA, OBBBA) and government efforts to control drug pricing, which collectively impact market dynamics and operational costs.

Comparison to Industry Standards

• Ozureprubart's Phase 2 data in CSU showed numerically greater improvement on the UAS7 endpoint and a numerically higher proportion of patients with UAS7=0 at all timepoints (Weeks 8, 12, and 16) compared to omalizumab Q4W, suggesting potential for improved efficacy or dosing convenience.
• A Phase 1 clinical trial comparing ozureprubart and omalizumab demonstrated that ozureprubart's median half-life was more than two times that of omalizumab at the same dose, leading to deeper and more sustained reduction of free IgE and higher total IgE accumulation.
• Tivumecirnon, in combination with pembrolizumab, showed greater confirmed objective response rate and progression-free survival in a Phase 1/2 trial for advanced checkpoint-naive non-small cell lung cancer than historically demonstrated by pembrolizumab monotherapy.
• Competitors in anti-IgE treatments for food allergy and CSU include companies such as LongBio Pharma, United Biopharma, and Yuhan, as well as Celldex, Otsuka, and Sanofi with late-stage clinical development products for CSU.
• The company competes with large, multinational pharmaceutical companies like AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Incyte, Kyowa Hakko Kirin, Merck, Novartis, Pfizer, Roche/Genentech, and Sanofi/Regeneron in the inflammatory diseases and cancer therapeutic areas.

Corporate Governance

Legal Proceedings

• Management believes there are currently no claims or actions pending against the company that would have a material adverse effect on its results of operations, financial condition, or cash flows.

Stakeholder Impact

• Shareholders: Experienced dilution from the recent public offering and reverse stock split. Potential for capital appreciation is tied to successful drug development. Principal stockholders maintain significant control. Future capital raises may lead to further dilution.
• Employees: Impacted by a workforce reduction of approximately 40% (47 people) in July 2024. Benefited from stock-based compensation plans (2025 Inducement Plan, 2025 Equity Incentive Plan, Amended ESPP) and an option repricing in November 2024, aimed at retention and motivation.
• Customers (future): Potential for new therapeutic options for inflammatory, immunological, and oncology diseases if drug candidates like ozureprubart and tivumecirnon achieve regulatory approval.
• Partners (Jeyou, Hanmi): Ongoing collaboration for the development and commercialization of ozureprubart and tivumecirnon, with Jeyou providing clinical drug supply for ozureprubart.
• Creditors: The company has incurred net losses and negative cash flows from operations, but the recent capital raise is expected to provide sufficient funds for at least the next 12 months, mitigating immediate liquidity concerns.

Next Steps

• Discuss next steps regarding development for CSU with the FDA and other regulatory authorities, aiming for Phase 3 clinical development for ozureprubart.
• Continue to incur substantial costs for research and development activities to advance drug candidates.
• Raise additional capital through equity, borrowings, or strategic alliances to support ongoing operations and development strategy.
• Seek a partner to further develop tivumecirnon outside the Hanmi Territory.
• Advance other programs into clinical development.
• Evaluate the impact of new accounting pronouncements (ASU 2024-03 and ASU 2023-09) on financial statements and disclosures.

Key Dates

Recommendation

While the positive Phase 2 data for ozureprubart and the substantial capital raise are strong positive indicators, the company remains in a clinical stage with a history of significant losses and an accumulated deficit. The cessation of the zelnecirnon program highlights the inherent risks in drug development. The recent capital raise provides a longer runway, but future profitability is uncertain and dependent on successful clinical development and commercialization, which are years away. The stock has high volatility, and while there are promising developments, the long-term risks and lack of immediate revenue generation suggest a 'hold' position for investors awaiting further de-risking of the pipeline.

Keywords

Biopharmaceutical, Immunology, Inflammatory diseases, Allergic diseases, Oncology, Drug development, Clinical trials, Ozureprubart, Tivumecirnon, CCR4 antagonist, IgE antibody, Food allergy, Chronic spontaneous urticaria, Non-small cell lung cancer, SEC filing, 10-Q, Biotech, Pharmaceutical